Celldex Therapeutics Inc (CLDX)
Healthcare
Biotechnology
38.10 $
-1.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Celldex Therapeutics Inc (CLDX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 92.3% of the shares are freely tradable; institutional investors hold 94.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
94.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
92.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
11.0%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
79Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Wellington Management Company LLP | 10.91 | 8,560,476 | +6.0 | 03/31/2026 |
| Kynam Capital Management, LP | 7.44 | 5,840,567 | -1.7 | 03/31/2026 |
| BlackRock Inc | 6.84 | 5,369,885 | -1.5 | 03/31/2026 |
| Vanguard Group Inc | 5.13 | 4,027,407 | +1.8 | 12/31/2025 |
| FMR Inc | 4.78 | 3,749,048 | -23.6 | 03/31/2026 |
| Point72 Asset Management, L.P. | 4.12 | 3,229,939 | +83.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.77 | 2,960,895 | +0.0 | 03/31/2026 |
| State Street Corp | 3.57 | 2,804,168 | -17.5 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Health Care Inv | 5.45 | 4,279,485 | +0.7 | 03/31/2026 |
| BB Biotech AG Ord | 4.53 | 3,557,669 | +7.6 | 09/30/2025 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.